Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Anaptysbio (ANAB) Invested Capital (2016 - 2025)

Anaptysbio's Invested Capital history spans 10 years, with the latest figure at $37.2 million for Q4 2025.

  • For Q4 2025, Invested Capital fell 47.49% year-over-year to $37.2 million; the TTM value through Dec 2025 reached $37.2 million, down 47.49%, while the annual FY2025 figure was $37.2 million, 47.49% down from the prior year.
  • Invested Capital reached $37.2 million in Q4 2025 per ANAB's latest filing, up from -$29.4 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $385.7 million in Q2 2021 to a low of -$44.7 million in Q2 2025.
  • Average Invested Capital over 5 years is $172.0 million, with a median of $134.4 million recorded in 2023.
  • Peak YoY movement for Invested Capital: increased 6.49% in 2021, then tumbled 552.81% in 2025.
  • A 5-year view of Invested Capital shows it stood at $356.4 million in 2021, then decreased by 26.46% to $262.1 million in 2022, then tumbled by 66.39% to $88.1 million in 2023, then dropped by 19.56% to $70.9 million in 2024, then plummeted by 47.49% to $37.2 million in 2025.
  • Per Business Quant, the three most recent readings for ANAB's Invested Capital are $37.2 million (Q4 2025), -$29.4 million (Q3 2025), and -$44.7 million (Q2 2025).